DVAX vs. BCRX, LGND, FOLD, CLDX, MNKD, INVA, NVAX, OPK, GERN, and RGLS
Should you be buying Dynavax Technologies stock or one of its competitors? The main competitors of Dynavax Technologies include BioCryst Pharmaceuticals (BCRX), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), MannKind (MNKD), Innoviva (INVA), Novavax (NVAX), OPKO Health (OPK), Geron (GERN), and Regulus Therapeutics (RGLS). These companies are all part of the "biotechnology" industry.
Dynavax Technologies vs.
Dynavax Technologies (NASDAQ:DVAX) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings, risk and community ranking.
In the previous week, Dynavax Technologies had 16 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 21 mentions for Dynavax Technologies and 5 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 0.91 beat Dynavax Technologies' score of 0.77 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.
Dynavax Technologies has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500.
97.0% of Dynavax Technologies shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 3.0% of Dynavax Technologies shares are held by insiders. Comparatively, 4.8% of BioCryst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Dynavax Technologies presently has a consensus target price of $24.00, indicating a potential upside of 132.54%. BioCryst Pharmaceuticals has a consensus target price of $16.56, indicating a potential upside of 49.08%. Given Dynavax Technologies' higher probable upside, equities analysts plainly believe Dynavax Technologies is more favorable than BioCryst Pharmaceuticals.
Dynavax Technologies has higher earnings, but lower revenue than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Dynavax Technologies, indicating that it is currently the more affordable of the two stocks.
BioCryst Pharmaceuticals received 22 more outperform votes than Dynavax Technologies when rated by MarketBeat users. Likewise, 67.16% of users gave BioCryst Pharmaceuticals an outperform vote while only 65.79% of users gave Dynavax Technologies an outperform vote.
Dynavax Technologies has a net margin of 9.85% compared to BioCryst Pharmaceuticals' net margin of -30.01%. Dynavax Technologies' return on equity of 4.22% beat BioCryst Pharmaceuticals' return on equity.
Summary
BioCryst Pharmaceuticals beats Dynavax Technologies on 10 of the 18 factors compared between the two stocks.
Get Dynavax Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for DVAX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dynavax Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:DVAX) was last updated on 6/10/2025 by MarketBeat.com Staff
